Amedeo Smart

Free Medical Literature Service

 

Amedeo

Ovarian Neoplasms
  Free Subscription

Articles published in
Cancer Res
    May 2024
  1. JOY JD, Malacrida B, Laforets F, Kotantaki P, et al
    Human 3D ovarian cancer models reveal malignant cell intrinsic and extrinsic factors that influence CAR T cell activity.
    Cancer Res. 2024 May 31. doi: 10.1158/0008-5472.CAN-23-3007.
    >> Share

    April 2024
  2. WATERS JA, Robinson M, Lujano-Olazaba O, Lucht C, et al
    Omental preadipocytes stimulate matrix remodeling and IGF signaling to support ovarian cancer metastasis.
    Cancer Res. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-2613.
    >> Share

    March 2024
  3. RAMANARAYANAN V, Oberdoerffer P
    AKTing on R Loops Makes for an ATRactive Target in Ovarian Cancer Therapy.
    Cancer Res. 2024;84:793-795.
    >> Share

    January 2024
  4. HUANG TT, Chiang CY, Nair JR, Wilson KM, et al
    AKT1 interacts with DHX9 to mitigate R-loop-induced replication stress in ovarian cancer.
    Cancer Res. 2024 Jan 19. doi: 10.1158/0008-5472.CAN-23-1908.
    >> Share

    December 2023
  5. HEO J, Kim YN, Shin S, Lee K, et al
    Serial circulating-tumor DNA analysis with a tumor naive next-generation sequencing panel detects minimal residual disease and predicts outcome in ovarian cancer.
    Cancer Res. 2023 Dec 1. doi: 10.1158/0008-5472.CAN-23-1429.
    >> Share

    October 2023
  6. BEDDOWS I, Fan H, Heinze K, Johnson BK, et al
    Cell state of origin impacts development of distinct endometriosis-related ovarian carcinoma histotypes.
    Cancer Res. 2023 Oct 24. doi: 10.1158/0008-5472.CAN-23-1362.
    >> Share

  7. ITO I, Yousef AMG, Chowdhury S, Dickson PN, et al
    Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma.
    Cancer Res. 2023;83:3184-3191.
    >> Share

    September 2023
  8. MUKHERJEE D, Previs RA, Haines C, Al Abo M, et al
    Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis.
    Cancer Res. 2023;83:2889-2907.
    >> Share

    August 2023
  9. YU ZC, Li T, Tully E, Huang P, et al
    Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors.
    Cancer Res. 2023;83:2750-2762.
    >> Share

  10. HU C, Nagaraj AB, Shimelis H, Montalban G, et al
    Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C.
    Cancer Res. 2023;83:2557-2571.
    >> Share

    May 2023
  11. CAO K, Zhang G, Yang M, Wang Y, et al
    Attenuation of sialylation augments antitumor immunity and improves response to immunotherapy in ovarian cancer.
    Cancer Res. 2023 May 12:CAN-22-3260. doi: 10.1158/0008-5472.CAN-22-3260.
    >> Share

  12. KELLIHER L, Lengyel E
    Understanding Long-Term Survival of Patients with Ovarian Cancer-The Tumor Microenvironment Comes to the Forefront.
    Cancer Res. 2023;83:1383-1385.
    >> Share

  13. PETRELLI A, Rizzolio S, Pietrantonio F, Bellomo SE, et al
    BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors.
    Cancer Res. 2023 May 2:OF1-OF12. doi: 10.1158/0008-5472.CAN-22-2620.
    >> Share

    April 2023
  14. LIU Y, Gusev A, Kraft P
    Germline Cancer Gene Expression Quantitative Trait Loci Are Associated with Local and Global Tumor Mutations.
    Cancer Res. 2023;83:1191-1202.
    >> Share

    February 2023
  15. FERRI-BORGOGNO S, Zhu Y, Sheng J, Burks JK, et al
    Spatial transcriptomics depict ligand-receptor crosstalk heterogeneity at the tumor-stroma interface in long-term ovarian cancer survivors.
    Cancer Res. 2023 Feb 14:CAN-22-1821. doi: 10.1158/0008-5472.CAN-22-1821.
    >> Share

    January 2023
  16. LLANO E, Todeschini AL, Felipe-Medina N, Corte-Torres MD, et al
    The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors.
    Cancer Res. 2023;83:239-250.
    >> Share

    December 2022
  17. HAWKINS SM, Nephew KP
    Unintended Consequences of Antibiotic Therapy on the Microbiome Delivers a Gut Punch in Ovarian Cancer.
    Cancer Res. 2022;82:4511-4512.
    >> Share

  18. ALSINA-SANCHIS E, Mulfarth R, Moll I, Bohn S, et al
    Endothelial RBPJ Is Essential for the Education of Tumor-Associated Macrophages.
    Cancer Res. 2022;82:4414-4428.
    >> Share

    November 2022
  19. WANG CK, Chen TJ, Tan GYT, Chang FP, et al
    MEX3A mediates p53 degradation to suppress ferroptosis and facilitate ovarian cancer tumorigenesis.
    Cancer Res. 2022 Nov 10. pii: 710535. doi: 10.1158/0008-5472.CAN-22-1159.
    >> Share

    October 2022
  20. ATIYA HI, Frisbie L, Goldfeld E, Orellana T, et al
    Endometriosis-associated mesenchymal stem cells support ovarian clear cell carcinoma through iron regulation.
    Cancer Res. 2022 Oct 11. pii: 709712. doi: 10.1158/0008-5472.CAN-22-1294.
    >> Share

  21. CHAMBERS LM, Esakov Rhoades EL, Bharti R, Braley C, et al
    Disruption of the gut microbiota confers cisplatin resistance in epithelial ovarian cancer.
    Cancer Res. 2022 Oct 7. pii: 709668. doi: 10.1158/0008-5472.CAN-22-0455.
    >> Share

  22. WANG Y, Huang P, Wang BG, Murdock T, et al
    Spatial transcriptomic analysis of ovarian cancer precursors reveals reactivation of IGFBP2 during pathogenesis.
    Cancer Res. 2022 Oct 7. pii: 709669. doi: 10.1158/0008-5472.CAN-22-1620.
    >> Share

  23. HO GY, Kyran EL, Bedo J, Wakefield MJ, et al
    Epithelial-to-mesenchymal transition supports ovarian carcinosarcoma tumorigenesis and confers sensitivity to microtubule-targeting with eribulin.
    Cancer Res. 2022 Oct 7. pii: 709667. doi: 10.1158/0008-5472.CAN-21-4012.
    >> Share

    September 2022
  24. ZHANG Y, Li J, Zhou Y, Li Z, et al
    And-1 Coordinates with the FANCM Complex to Regulate Fanconi Anemia Signaling and Cisplatin Resistance.
    Cancer Res. 2022;82:3249-3262.
    >> Share

    August 2022
  25. WANG Y, Xie H, Chang X, Hu W, et al
    Single-cell dissection of the multiomic landscape of high-grade serous ovarian cancer.
    Cancer Res. 2022 Aug 15. pii: 707741. doi: 10.1158/0008-5472.CAN-21-3819.
    >> Share

    July 2022
  26. CHENG L, Zhou S, Zhou S, Shi K, et al
    Dual inhibition of CDK12/CDK13 targets both tumor and immune cells in ovarian cancer.
    Cancer Res. 2022 Jul 20. pii: 707082. doi: 10.1158/0008-5472.CAN-22-0222.
    >> Share

    April 2022
  27. PELLEGRINO B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, et al
    Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    Cancer Res. 2022;82:1646-1657.
    >> Share

    March 2022
  28. ZHANG S, Yan C, Millar DG, Yang Q, et al
    Antibody-Peptide Epitope Conjugates for Personalized Cancer Therapy.
    Cancer Res. 2022;82:773-784.
    >> Share

    February 2022
  29. GHILARDI C, Moreira Barbosa C, Brunelli L, Ostano P, et al
    PGC1alpha/beta EXPRESSION PREDICTS THERAPEUTIC RESPONSE TO OXIDATIVE PHOSPHORYLATION INHIBITION IN OVARIAN CANCER.
    Cancer Res. 2022 Feb 7. pii: 0008-5472.CAN-21-1223.
    >> Share

    November 2021
  30. KANAKKANTHARA A, Hou X, Ekstrom TL, Zanfagnin V, et al
    Repurposing ceritinib induces DNA damage and enhances PARP inhibitor responses in high-grade serous ovarian carcinoma.
    Cancer Res. 2021 Nov 22. pii: 0008-5472.CAN-21-0732.
    >> Share

  31. JAVELLANA M, Eckert MA, Heide J, Zawieracz K, et al
    Neoadjuvant chemotherapy induces genomic and transcriptomic changes in ovarian cancer.
    Cancer Res. 2021 Nov 4. pii: 0008-5472.CAN-21-1467.
    >> Share

    October 2021
  32. RAY U, Jung DB, Jin L, Xiao Y, et al
    Targeting LRRC15 inhibits metastatic dissemination of ovarian cancer.
    Cancer Res. 2021 Oct 15. pii: 0008-5472.CAN-21-0622.
    >> Share

    September 2021
  33. LECKER LS, Berlato C, Maniati E, Delaine-Smith R, et al
    TGFBI production by macrophages contributes to an immunosuppressive microenvironment in ovarian cancer.
    Cancer Res. 2021 Sep 24. pii: 0008-5472.CAN-21-0536.
    >> Share

  34. ZUNDELL JA, Fukumoto T, Lin J, Fatkhudinov N, et al
    Targeting the IRE1alpha/XBP1 Endoplasmic Reticulum Stress Response Pathway in ARID1A-Mutant Ovarian Cancers.
    Cancer Res. 2021 Sep 21. pii: 0008-5472.CAN-21-1545.
    >> Share

    August 2021
  35. MCDONALD JI, Diab N, Arthofer E, Hadley M, et al
    Epigenetic therapies in ovarian cancer alter repetitive element expression in a TP53-dependent manner.
    Cancer Res. 2021 Aug 25. pii: 0008-5472.CAN-20-4243.
    >> Share

  36. GEETHADEVI A, Nair A, Parashar D, Ku Z, et al
    Oncostatin M Receptor-targeted antibodies suppress STAT3 signaling and inhibit ovarian cancer growth.
    Cancer Res. 2021 Aug 11. pii: 0008-5472.CAN-21-0483.
    >> Share

    July 2021
  37. NESIC K, Kondrashova O, Hurley RM, McGehee CD, et al
    Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma.
    Cancer Res. 2021 Jul 28. pii: 0008-5472.CAN-21-0774.
    >> Share

  38. TENG K, Ford MJ, Harwalkar K, Li Y, et al
    Modeling High-grade serous ovarian carcinoma using a combination of in vivo fallopian tube electroporation and CRISPR-Cas9-mediated genome editing.
    Cancer Res. 2021 Jul 23. pii: 0008-5472.CAN-20-1518.
    >> Share

    June 2021
  39. PATEL M, Wang Y, Bartom ET, Dhir R, et al
    The ratio of toxic-to-nontoxic microRNAs predicts platinum sensitivity in ovarian cancer.
    Cancer Res. 2021 Jun 15. pii: 0008-5472.CAN-21-0953.
    >> Share

  40. CHEN L, Zhai Y, Wang Y, Fearon ER, et al
    Altering the Microbiome Inhibits Tumorigenesis in a Mouse Model of Oviductal High-Grade Serous Carcinoma.
    Cancer Res. 2021;81:3309-3318.
    >> Share

    May 2021
  41. FARKKILA A, Rodriguez A, Oikkonen J, Gulhan DC, et al
    Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells.
    Cancer Res. 2021;81:2774-2787.
    >> Share

    April 2021
  42. SCHOUTROP E, El-Serafi I, Poiret T, Zhao Y, et al
    Mesothelin-specific CAR T cells target ovarian cancer.
    Cancer Res. 2021 Apr 1. pii: 0008-5472.CAN-20-2701.
    >> Share

    February 2021
  43. BELUR NAGARAJ A, Knarr M, Sekhar S, Connor RS, et al
    The miR-181a-SFRP4 axis regulates Wnt activation to drive stemness and platinum resistance in ovarian cancer.
    Cancer Res. 2021 Feb 11. pii: 0008-5472.CAN-20-2041.
    >> Share

    January 2021
  44. SHRESTHA R, Llaurado Fernandez M, Dawson A, Hoenisch J, et al
    Multiomics characterization of low-grade serous ovarian carcinoma identifies potential biomarkers of MEK inhibitor sensitivity and therapeutic vulnerability.
    Cancer Res. 2021 Jan 13. pii: 0008-5472.CAN-20-2222.
    >> Share

    December 2020
  45. KARLSSON T, Johansson T, Hoglund J, Ek WE, et al
    Time-dependent effects of oral contraceptive use on breast, ovarian and endometrial cancers.
    Cancer Res. 2020 Dec 17. pii: 0008-5472.CAN-20-2476.
    >> Share

    November 2020
  46. DRERUP JM, Deng Y, Pandeswara SL, Padron AS, et al
    CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
    Cancer Res. 2020;80:5063-5075.
    >> Share

  47. WANG Y, Zhao G, Condello S, Huang H, et al
    Frizzled-7 Identifies Platinum Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis.
    Cancer Res. 2020 Nov 10. pii: 0008-5472.CAN-20-1488.
    >> Share

  48. WAN C, Keany MP, Dong H, Al-Alem LF, et al
    Enhanced efficacy of simultaneous PD-1 and PD-L1 immune checkpoint blockade in high grade serous ovarian cancer.
    Cancer Res. 2020 Nov 6. pii: 0008-5472.CAN-20-1674.
    >> Share

    October 2020
  49. PARASHAR D, Nair B, Geethadevi A, George J, et al
    Peritoneal Spread of Ovarian Cancer harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.
    Cancer Res. 2020 Oct 21. pii: 0008-5472.CAN-19-3717.
    >> Share

  50. SHEN YA, Hong J, Asaka R, Asaka S, et al
    Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
    Cancer Res. 2020;80:4514-4526.
    >> Share

    September 2020
  51. TAMURA N, Shaikh N, Muliaditan D, Soliman TN, et al
    Specific mechanisms of chromosomal instability indicate therapeutic sensitivities in high-grade serous ovarian carcinoma.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-19-0852.
    >> Share

  52. HUANG TT, Brill E, Nair JR, Zhang X, et al
    Targeting the PI3K/mTOR pathway augments CHK1 inhibitor-induced replication stress and antitumor activity in high-grade serous ovarian cance.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-20-1439.
    >> Share

  53. AZAR WJ, Christie EL, Mitchell C, Liu DS, et al
    Non-canonical IL-6 signaling-mediated activation of YAP regulates cell migration and invasion in ovarian clear cell cancer.
    Cancer Res. 2020 Sep 11. pii: 0008-5472.CAN-19-3044.
    >> Share

  54. CARLES A, Trigo-Gonzalez G, Cao Q, Cheng SG, et al
    The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity.
    Cancer Res. 2020;80:3480-3491.
    >> Share

  55. WEIS-BANKE SE, Lerdrup M, Kleine-Kohlbrecher D, Mohammad F, et al
    Mutant FOXL2(C134W) Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors.
    Cancer Res. 2020;80:3466-3479.
    >> Share

  56. TUBEUF H, Caputo SM, Sullivan T, Rondeaux J, et al
    Calibration of Pathogenicity Due to Variant-Induced Leaky Splicing Defects by Using BRCA2 Exon 3 as a Model System.
    Cancer Res. 2020;80:3593-3605.
    >> Share

    August 2020
  57. GEISTLINGER L, Oh S, Ramos M, Schiffer L, et al
    Multi-omic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma.
    Cancer Res. 2020 Aug 3. pii: 0008-5472.CAN-20-0521.
    >> Share

    April 2020
  58. MEULEMANS L, Mesman RLS, Caputo SM, Krieger S, et al
    Skipping Nonsense to Maintain Function: The Paradigm of BRCA2 Exon 12.
    Cancer Res. 2020;80:1374-1386.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016